Suppr超能文献

相似文献

1
Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.
Prog Neurobiol. 2017 Jul;154:21-36. doi: 10.1016/j.pneurobio.2017.04.004. Epub 2017 Apr 23.
2
Hypomethylation of intron1 of α-synuclein gene does not correlate with Parkinson's disease.
Mol Brain. 2017 Feb 7;10(1):6. doi: 10.1186/s13041-017-0285-z.
3
Unraveling the Complex Interplay between Alpha-Synuclein and Epigenetic Modification.
Int J Mol Sci. 2023 Apr 2;24(7):6645. doi: 10.3390/ijms24076645.
4
The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
Brain. 2017 Apr 1;140(4):878-886. doi: 10.1093/brain/aww227.
5
Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease.
EMBO Mol Med. 2021 Feb 5;13(2):e12188. doi: 10.15252/emmm.202012188. Epub 2021 Jan 11.
6
Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression.
Nature. 2016 May 5;533(7601):95-9. doi: 10.1038/nature17939. Epub 2016 Apr 20.
7
DNA methylation in Parkinson's disease.
J Neurochem. 2016 Oct;139 Suppl 1:108-120. doi: 10.1111/jnc.13646. Epub 2016 Jun 10.
8
Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus.
Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14280-14289. doi: 10.1073/pnas.1900576116. Epub 2019 Jun 24.
9

引用本文的文献

1
Alpha-synuclein abundance and localization are regulated by the RNA-binding protein PUMILIO1.
Cell Rep. 2025 Aug 26;44(8):116145. doi: 10.1016/j.celrep.2025.116145. Epub 2025 Aug 13.
2
Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease.
Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102635. doi: 10.1016/j.omtn.2025.102635. eCollection 2025 Sep 9.
4
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.
Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405.
6
The interplay of iron, oxidative stress, and α-synuclein in Parkinson's disease progression.
Mol Med. 2025 Apr 26;31(1):154. doi: 10.1186/s10020-025-01208-3.
8
Novel Therapeutic Horizons: Targeting in Parkinson's Disease.
Biomolecules. 2024 Aug 6;14(8):949. doi: 10.3390/biom14080949.
9
Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson's disease and synucleinopathies.
Front Cell Neurosci. 2024 Jan 5;17:1328269. doi: 10.3389/fncel.2023.1328269. eCollection 2023.

本文引用的文献

1
Elevated 5hmC levels characterize DNA of the cerebellum in Parkinson's disease.
NPJ Parkinsons Dis. 2017 Feb 1;3:6. doi: 10.1038/s41531-017-0007-3. eCollection 2017.
3
Hypomethylation of intron1 of α-synuclein gene does not correlate with Parkinson's disease.
Mol Brain. 2017 Feb 7;10(1):6. doi: 10.1186/s13041-017-0285-z.
5
Epigenetic Biomarkers for Parkinson's Disease: From Diagnostics to Therapeutics.
J Parkinsons Dis. 2017;7(1):1-12. doi: 10.3233/JPD-160914.
6
DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies.
Psychiatry Clin Neurosci. 2017 Jan;71(1):28-35. doi: 10.1111/pcn.12462. Epub 2016 Nov 3.
7
The rs3756063 polymorphism is associated with SNCA methylation in the Chinese Han population.
J Neurol Sci. 2016 Aug 15;367:11-4. doi: 10.1016/j.jns.2016.05.037. Epub 2016 May 19.
8
Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression.
Nature. 2016 May 5;533(7601):95-9. doi: 10.1038/nature17939. Epub 2016 Apr 20.
9
Direct α-synuclein promoter transactivation by the tumor suppressor p53.
Mol Neurodegener. 2016 Feb 2;11:13. doi: 10.1186/s13024-016-0079-2.
10
DNA methylation levels of α-synuclein intron 1 in the aging brain.
Neurobiol Aging. 2015 Dec;36(12):3334.e7-3334.e11. doi: 10.1016/j.neurobiolaging.2015.08.028. Epub 2015 Sep 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验